American Capital Advisory’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$30.9K Buy
530
+6
+1% +$354 0.01% 269
2026
Q2
$29.4K Buy
524
+8
+2% +$416 0.01% 268
2026
Q1
$24.8K Hold
516
– – 0.01% 269
2025
Q4
$19.9K Sell
516
-197
-28% -$7.51K 0.01% 281
2025
Q3
$25.2K Sell
713
-3
-0.4% -$109 0.01% 248
2025
Q2
$25.8K Buy
716
+12
+2% +$398 0.01% 240
2025
Q1
$21.9K Buy
704
+4
+0.6% +$127 0.01% 255
2024
Q4
$17.9K Hold
700
– – 0.01% 262
2024
Q3
$19.8K Sell
700
-200
-22% -$5.54K 0.01% 250
2024
Q2
$25.3K Sell
900
-100
-10% -$2.77K 0.02% 201
2024
Q1
$36K Buy
1,000
+100
+11% +$2.95K 0.03% 162
2023
Q4
$25.3K Buy
+900
New +$24.7K 0.02% 201

Other funds holding RPRX

American Capital Advisory's RPRX Position: Q3 2026 in Review

American Capital Advisory increased its Royalty Pharma (RPRX) stake by 1.1% in Q3 2026, buying an estimated $354 and bringing the position to 530 shares worth $30.9K. The position accounts for 0.01% of the portfolio, ranked #269.

American Capital Advisory first reported a position in RPRX in Q4 2023 and has held it in 12 quarters since. The position peaked at $36K in Q1 2024. 705 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • American Capital Advisory held 530 shares of Royalty Pharma worth $30.9K as of Q3 2026.
  • American Capital Advisory bought 6 Royalty Pharma shares in Q3 2026, an estimated $354.
  • Royalty Pharma made up 0.01% of American Capital Advisory's portfolio in Q3 2026, its #269 holding.
  • American Capital Advisory first reported a position in Royalty Pharma in Q4 2023 and has held it in 12 quarters since.
  • American Capital Advisory's Royalty Pharma position peaked at $36K in Q1 2024.
  • 705 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on American Capital Advisory's 13F filing for Q3 2026, filed 28 Oct 2026.